Recent Surge: Minerva Neurosciences (NERV) has seen a dramatic spike in attention on X following news of a $200 million financing deal. Posts highlight the stock’s surge of over 300% in a single day, driven by optimism around funding for a Phase 3 trial of roluperidone for schizophrenia treatment. The buzz centers on the potential for a significant breakthrough in central nervous system therapies.
Investor Caution: Despite the excitement, some discussions on X warn of risks like dilution and regulatory hurdles. Many are intrigued by the FDA’s involvement in confirming a new trial, but skepticism remains about execution and long-term outcomes. This mix of hope and caution keeps the conversation lively and dynamic.
Note: This discussion summary was generated from an AI condensation of post data.
Minerva Neurosciences Hedge Fund Activity
We have seen 8 institutional investors add shares of Minerva Neurosciences stock to their portfolio, and 9 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- APELLA CAPITAL, LLC added 18,375 shares (+87.8%) to their portfolio in Q3 2025, for an estimated $38,679
- CITADEL ADVISORS LLC removed 12,915 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $22,213
- ADAR1 CAPITAL MANAGEMENT, LLC added 12,406 shares (+inf%) to their portfolio in Q2 2025, for an estimated $21,338
- RENAISSANCE TECHNOLOGIES LLC removed 3,097 shares (-2.7%) from their portfolio in Q2 2025, for an estimated $5,326
- WELLS FARGO & COMPANY/MN removed 1,938 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $3,333
- GEODE CAPITAL MANAGEMENT, LLC removed 1,107 shares (-1.4%) from their portfolio in Q2 2025, for an estimated $1,904
- UBS GROUP AG removed 746 shares (-46.0%) from their portfolio in Q2 2025, for an estimated $1,283
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
